MDNews - Lower Hudson/Bronx

September 2012

Issue link: https://viewer.e-digitaledition.com/i/82081

Contents of this Issue

Navigation

Page 22 of 43

CANCER UPDATE Collaborating for Superior Cancer Care Milan Kinkhabwala, M.D. AT ALTHOUGH THE INCIDENCE OF LIVER CANCER IS INCREASING IN THE UNITED STATES, A DIZZYING ARRAY OF NEW, ADVANCED THERAPEUTIC OPTIONS, SOME WITH THE POTENTIAL FOR CURE, ARE AVAILABLE AT LEADING CANCER CENTERS SUCH AS THE MONTEFIORE EINSTEIN CENTER FOR CANCER CARE. MONTEFIORE EINSTEIN CENTER for Cancer Care, the first-class team of clinicians and scientists of the Hepatobiliary Cancer Program are able to rapidly assess new patients in a multidisciplinary center and usually develop individualized treatment plans the same day. The team includes liver cancer surgeons, hepatologists, medical and radiation oncologists, and interventional oncologists all in one setting. All types of benign and malignant liver tumors are evaluated at The Center for Cancer Care, including cholangiocarcinoma (biliary cancer), hepatocellular cancer (HCC) and secondary cancer that has metastasized to the liver. "To develop an appropriate treatment plan for patients with liver cancer, we use a multimodality approach to care that is individualized based on each patient's char- acteristics," says Milan Kinkhabwala, M.D., Director of the Hepatobiliary Cancer Program at Montefiore Einstein Center for Cancer Care, Chief of the Division of Transplantation at Montefiore Medical Center and professor in the Department of Surgery at Albert Einstein College of Medicine. "We can offer a full range of options, from complex liver surgery and liver transplantation to minimally invasive and nonoperative approaches to eradicate liver tumors. Some patients may not be candidates for surgery, but we are still able to offer them curative options, such as transcatheter embolization, stereotactic radiosurgery and percutaneous tumor abla- tion. In many cases, these therapies can be utilized as a bridge to transplantation." All new patient cases are discussed by a dedicated liver tumor board, often on the same day as the patient visit. The entire team reviews the clinical details of each case and discusses all options for treatment of the cancer, as well as other conditions such as cirrhosis, which often complicate liver cancer. This broad expertise and range of in-house treatment options are available at only a handful of medical centers nationwide. Complex liver surgery is routine at Montefiore, including procedures that cannot even be considered at most institutions due to a lack of infrastructure and expertise. For tumors considered unresectable at many cancer hospitals, Montefiore cardiac and liver surgeons — working in concert with their anesthesia colleagues — are able to create controlled temporary cardiac arrest (hypothermic arrest) during surgery to permit resection of tumors in locations previously considered unapproachable. Dr. Kinkhabwala explains that, in some cases, these advanced treatments may allow patients who were previously considered unsuitable for liver replacement with transplant to qualify, or even nullify the need, for transplantation. Montefiore Einstein Center for Transplantation's status as one of the leading programs in the country enables physicians to place early-stage liver cancer patients on the transplant waiting list while continuing chemotherapy and radiation treatment. Advancing Research An emphasis on innovation and translational research allows patients at Montefiore Einstein Center for Cancer Care the unique opportunity to participate in clinical trials. For example, patients with colorectal cancer that has metastasized to the liver are currently being considered for a trial of ThermoDox, which utilizes heat-activated liposomal doxorubicin in conjunction with radiofrequency ablation (RFA). This approach offers the promise of improving results of local tumor control in the liver compared to conventional radiofrequency ablation. Montefiore's surgeons and interventional oncologists are experts in ablation of liver tumors using RFA, as well as new platforms such as microwave ablation. For patients with advanced metastatic disease to the liver, isolated hepatic perfu- sion (IHP) is offered at Montefiore, one of only four such locations for this therapy in the United States. IHP is a surgical pro- cedure in which the liver is perfused with high doses of hyperthermic chemotherapy to achieve reduction in size of metastatic lesions, potentially prolonging survival. Researchers at the Marion Bessin Liver Research Center and the National Institutes of Health-designated Cancer Center at Albert Einstein College of Medicine are at the forefront of basic science in liver disease, including cancer proteomics, the study of proteins in malignancy. Researchers believe analysis of serum from patients with liver cancer may permit development of a protein signature test for early detection of liver cancers in at-risk patients, such as those with hepatitis C or B. For more informat ion about the Montefiore Einstein Center for Cancer Care Hepatobiliary Cancer Program, visit www.montefiore.org/ hepatobiliary-tumors- liver-cancer. n MDNEWS.COM n MD NEWS Lower Hudson/Bronx | 23 +++++++++++++++++++++++ + +++ +++ +++++++++++++++++++++++ +

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - September 2012